Skip to content

Clinical study of oxaliplatin for postoperative analgesia in orthopedic trauma patients

Clinical study of oxaliplatin for postoperative analgesia in orthopedic trauma patients

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093955
Enrollment
Unknown
Registered
2024-12-13
Start date
2024-07-16
Completion date
Unknown
Last updated
2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain

Interventions

Test group:Postoperative analgesia was administered using a patient-controlled intravenous analgesia pump. The experimental group received a postoperative analgesia formula consisting of 159.5ml of 0.
Control group:The postoperative analgesic formula for the control group: 180ml of 0.9% sodium chloride injection+15mg of tropisetron+150ug of sufentanil citrate injection. The analgesic pump parameter

Sponsors

Sichuan Provincial Orthopedic Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Single site traumatic fracture of lower limbs; 2. 18 years old <= age <= 75 years old, gender not limited; 3. ASA classification levels I-III; 4. Understand the research protocol and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Known or suspected multiple injuries; 2. Known or suspected to have serious infectious diseases; 3. History of opioid allergy; 4. Use drugs that may affect analgesic response (central alpha adrenergic, antiepileptic drugs, neurostimulants, antidepressants, or antipsychotics), with no fixed dose administered for >= 30 days before surgery; 5. Use oral or parenteral corticosteroids within 3 months before surgery; 6. Patients with liver and kidney dysfunction during screening, and with Child Pugh classification of liver function not reaching A or B after treatment, as well as creatinine levels greater than 158 µ mol/L; 7. Other postoperative exclusion criteria include evidence of hemodynamic instability or respiratory dysfunction, surgical/anesthesia complications, and events that may affect data interpretation.

Design outcomes

Primary

MeasureTime frame
Nausea;Vomiting;

Secondary

MeasureTime frame
pain score;Sedation rating;Sleep quality score;Types and dosages of remedial antiemetic and analgesic drugs;

Countries

China

Contacts

Public ContactLi Su

Sichuan Provincial Orthopedic Hospital

suli1981@163.com+86 134 3845 6433

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026